A recent study highlighting the long-term efficacy of inhaled cannabis for chronic pain brings into sharp focus the rigorous Good Distribution Practice (GDP) requirements and controlled drug compliance obligations for UK medicinal cannabis operators. Boards, RPs, and founders must ensure robust systems are in place.
How to design, validate and monitor temperature-controlled storage and transport for UK medical cannabis under EU GDP — mapping, excursions, qualified couriers, and inspection evidence.
A practical guide to maintaining a Misuse of Drugs Regulations 2001 controlled drugs register for medical cannabis — what to record, how to reconcile, and what inspectors actually look for.
How UK medical cannabis wholesalers should verify customer authorisation under EU GDP — practical bona fide checks, evidence, and on-going monitoring that hold up at MHRA inspection.
How to prepare for an MHRA Good Distribution Practice (GDP) inspection — from documentation and premises to staff competency and CAPA management.
How the Home Office Domestic Schedule 2 Controlled Drugs Licence works for UK medical cannabis importers — eligibility, premises, key personnel, CDLO process, import/export licences and the MHRA WDA(H) interlock.
A practical, board-level walkthrough of the MHRA Wholesale Dealer's Licence (WDA(H)) application for UK medical cannabis importers — site, RP, QMS, GDP evidence and the Home Office Schedule 2 interlock.
A recent MHRA enforcement action against a licensed medicinal cannabis importer has sent ripples through the sector. While the immediate focus was on GDP lapses and the Responsible Person's (RP) role, a deeper, often overlooked issue arises: the board's ultimate accountability for ensuring effective RP oversight and controlled drug compliance. This isn't just about ticking boxes; it's about embedding a culture of quality from top to bottom.
For UK medicinal cannabis and CBD businesses, the regulatory landscape shifts constantly. By late 2026, understanding the nuances of MHRA Responsible Person duties, robust controlled drug compliance, and effective GDP audit preparation will be paramount for securing and maintaining crucial licences.
A step-by-step guide to qualifying as a Responsible Person under MHRA and GDP — covering training, licensing and the operational expectations regulators look for.
